Latest News and Press Releases
Want to stay updated on the latest news?
-
~30% Quarterly Revenue Growth Driven by Amtagvi Demand Gross Margin Increased to 50% FY25 Revenue of $264M Achieved Annual Guidance U.S. FDA Fast Track Designation Granted for Lifileucel in...
-
50% Objective Response Rate (ORR) in Advanced Sarcomas Significant Market Opportunity with More than 8,000 Patients Diagnosed Annually in the U.S. and Europe SAN CARLOS, Calif., Feb. 24, 2026 ...
-
Turnstone Biologics presents preclinical data highlighting potential for Selected TIL therapy in solid tumors at SITC 2024
-
Turnstone Biologics announces strategic restructuring to prioritize portfolio and extend financial runway.
-
Turnstone reports second quarter 2024 financial results and provides recent business highlights
-
ORR of 25% and 50% DCR observed in first four evaluable patients treated with TIDAL-01 with advanced CRC
-
Turnstone Biologics Reports First Quarter 2024 Financial Results and Provides Recent Business Highlights
-
Dr. Sammy Farah, Turnstone's President and CEO, to present at the 2024 Bank of America Securities Health Care Conference in Las Vegas, NV.
-
Turnstone Biologics appoints biotechnology industry veteran, William Waddill, to its Board of Directors.
-
Turnstone reports fourth quarter and full year 2023 financial results and provides recent business highlights.